See the DrugPatentWatch profile for taltz
Yes, Taltz Is an Injection
Taltz (ixekizumab) is administered as a subcutaneous injection, either self-injected by patients at home using prefilled autoinjectors or syringes, or given by a healthcare provider.[1]
How Taltz Injections Work
Patients typically inject 80 mg (one autoinjector or syringe) under the skin in the thigh, abdomen, or upper arm every 4 weeks after initial loading doses. The autoinjector design minimizes needle pain, with most injections taking seconds.[1][2]
Who Uses Taltz Injections and Why
Taltz treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in adults and children over 6. As a biologic IL-17A inhibitor, it targets inflammation that topical treatments can't reach, requiring injection for systemic delivery.[1]
Injection Schedules by Condition
- Psoriasis: 160 mg at week 0, then 80 mg every 4 weeks.
- Psoriatic arthritis or axial conditions: Same as psoriasis, sometimes with methotrexate.
Doses stay consistent long-term; no oral form exists.[1]
Common Injection-Site Reactions
Redness, itching, or pain at the site affects about 20% of users, usually mild and short-lived. Rotate sites to avoid issues; infections are rare but monitored.[1][3]
Storage and Travel Tips for Injections
Keep autoinjectors refrigerated at 2-8°C (36-46°F); allow to warm to room temperature for 30 minutes before injecting. Unrefrigerated, they last up to 5 days. Travel with a cooler pack.[1]
Alternatives to Taltz Injections
- Other injections: Cosentyx (secukinumab, similar IL-17 inhibitor), Stelara (ustekinumab).
- Infusions: Tremfya (guselkumab, subcutaneous).
- Pills: Otezla (apremilast, non-biologic); Sotyktu (deucravacitinib, JAK inhibitor).
No generics or biosimilars for Taltz yet; patents extend to 2032-2034.1
[1]: Taltz.com (official prescribing information)
[2]: FDA Label for Ixekizumab
[3]: Clinicaltrials.gov (IXORA studies)